$AAGH
America Great Health

2023 Q2 Form 10-Q Financial Statement

#000118518523000567 Filed on May 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $74.69K $39.45K $2.740K
YoY Change -28.63% 1339.85% -98.6%
Cost Of Revenue $30.00 $190.00 $360.00
YoY Change -100.0% -47.22% -99.75%
Gross Profit $74.66K $39.26K $2.380K
YoY Change -105.03% 1549.66% -95.39%
Gross Profit Margin 99.96% 99.52% 86.86%
Selling, General & Admin $232.2K $151.0K $649.6K
YoY Change -92.85% -76.76% 558.26%
% of Gross Profit 311.06% 384.59% 27295.8%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.700K $3.700K
YoY Change -37.39%
% of Gross Profit 4.96% 9.42%
Operating Expenses $232.2K $151.0K $649.6K
YoY Change -92.85% -76.76% 558.33%
Operating Profit -$157.6K -$111.7K -$647.3K
YoY Change -96.67% -82.74% 1275.69%
Interest Expense -$85.22K $101.9K -$55.28K
YoY Change -55.36% -284.37% 2459.26%
% of Operating Profit
Other Income/Expense, Net -$20.00 -$101.9K $93.01K
YoY Change -128.57% -209.57%
Pretax Income -$242.8K -$213.6K -$609.5K
YoY Change -95.07% -64.95% 1138.38%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$241.8K -$213.6K -$609.5K
YoY Change -95.03% -64.95% 1138.38%
Net Earnings / Revenue -323.72% -541.54% -22245.62%
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00 -$28.90
COMMON SHARES
Basic Shares Outstanding 21.09B shares 21.09B shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $54.15K $55.57K $106.3K
YoY Change -13.55% -47.72% 320.99%
Cash & Equivalents $54.15K $55.57K $106.3K
Short-Term Investments
Other Short-Term Assets $16.96K $16.97K $10.25K
YoY Change 0.0% 65.56%
Inventory $108.4K $113.8K $148.6K
Prepaid Expenses
Receivables $0.00 $1.227K
Other Receivables $0.00 $0.00
Total Short-Term Assets $179.5K $187.5K $345.8K
YoY Change -8.71% -45.77% 851.31%
LONG-TERM ASSETS
Property, Plant & Equipment $57.69K $61.39K $118.7K
YoY Change 144.27% -48.27% -14.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.218K $8.218K $2.700K
YoY Change -40.6% 204.37%
Total Long-Term Assets $119.7K $121.3K $121.4K
YoY Change -14.26% -0.09% -12.8%
TOTAL ASSETS
Total Short-Term Assets $179.5K $187.5K $345.8K
Total Long-Term Assets $119.7K $121.3K $121.4K
Total Assets $299.1K $308.8K $467.2K
YoY Change -11.01% -33.9% 166.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.451M $1.426M $1.581M
YoY Change 0.91% -9.82% 3662.57%
Accrued Expenses $41.92K $39.82K $52.60K
YoY Change -40.87% -24.3% 5.12%
Deferred Revenue
YoY Change
Short-Term Debt $705.2K $243.3K $160.0K
YoY Change 283.41% 52.04%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.092M $2.586M $2.362M
YoY Change 12.13% 9.45% 516.83%
LONG-TERM LIABILITIES
Long-Term Debt $1.123M $1.533M $1.032M
YoY Change 8.82% 48.54%
Other Long-Term Liabilities $609.9K $546.7K $174.9K
YoY Change 49.83% 212.69% 96.11%
Total Long-Term Liabilities $1.733M $1.533M $1.207M
YoY Change 20.42% 27.02% 1253.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.092M $2.586M $2.362M
Total Long-Term Liabilities $1.733M $1.533M $1.207M
Total Liabilities $4.825M $4.666M $3.569M
YoY Change 14.97% 30.71% 655.98%
SHAREHOLDERS EQUITY
Retained Earnings -$9.183M -$8.941M
YoY Change 9.04%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.451M -$4.283M -$3.102M
YoY Change
Total Liabilities & Shareholders Equity $299.1K $308.8K $467.2K
YoY Change -11.01% -33.9% 166.12%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$241.8K -$213.6K -$609.5K
YoY Change -95.03% -64.95% 1138.38%
Depreciation, Depletion And Amortization $3.700K $3.700K
YoY Change -37.39%
Cash From Operating Activities -$141.1K -$396.1K -$707.1K
YoY Change -12.32% -43.98% 650.82%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $97.50K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 140.7K 400.5K 607.2K
YoY Change 20.11% -34.04% 969.32%
NET CHANGE
Cash From Operating Activities -141.1K -396.1K -707.1K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 140.7K 400.5K 607.2K
Net Change In Cash -450.0 4.310K -99.96K
YoY Change -98.97% -104.31% 167.27%
FREE CASH FLOW
Cash From Operating Activities -$141.1K -$396.1K -$707.1K
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$141.1K -$396.1K -$707.1K
YoY Change -12.32% -43.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-27873
dei Entity Registrant Name
EntityRegistrantName
America Great Health
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0178621
dei Entity Address Address Line1
EntityAddressAddressLine1
1609 W Valley Blvd Unit 338A
dei Entity Address City Or Town
EntityAddressCityOrTown
Alhambra
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91803
dei City Area Code
CityAreaCode
888
dei Local Phone Number
LocalPhoneNumber
988-1333
dei Security12b Title
Security12bTitle
N/A
dei Trading Symbol
TradingSymbol
N/A
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21093818148 shares
CY2023Q1 us-gaap Cash
Cash
55568 usd
CY2022Q2 us-gaap Cash
Cash
62643 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1227 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
918 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
113759 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
116060 usd
CY2023Q1 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
16965 usd
CY2022Q2 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
16964 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
187519 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
196585 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
39822 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
93886 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8218 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8218 usd
CY2023Q1 us-gaap Deposit Assets
DepositAssets
11836 usd
CY2022Q2 us-gaap Deposit Assets
DepositAssets
13836 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61389 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23618 usd
CY2023Q1 us-gaap Assets
Assets
308784 usd
CY2022Q2 us-gaap Assets
Assets
336143 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1425826 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1437522 usd
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1726 usd
CY2022Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
102 usd
CY2023Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
243271 usd
CY2022Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
183932 usd
CY2023Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
215717 usd
CY2022Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
334112 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
476459 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
573859 usd
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
183019 usd
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
157000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
39822 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
70895 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2585840 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2757422 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22991 usd
CY2023Q1 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
546738 usd
CY2022Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
384073 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1533138 usd
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1032138 usd
CY2023Q1 us-gaap Liabilities
Liabilities
4665716 usd
CY2022Q2 us-gaap Liabilities
Liabilities
4196624 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21093818148 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21093818148 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21090218148 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21090218148 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
0 usd
us-gaap Interest Expense
InterestExpense
136142 usd
CY2023Q1 us-gaap Other Income
OtherIncome
6 usd
CY2022Q1 us-gaap Other Income
OtherIncome
93010 usd
us-gaap Other Income
OtherIncome
34999 usd
us-gaap Other Income
OtherIncome
93045 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-101913 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
37727 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-199460 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-43097 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4657597 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4619991 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
625 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
160 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8941483 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8421849 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4283261 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-3801698 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
-73671 usd
CY2022Q2 us-gaap Minority Interest
MinorityInterest
-58783 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4356932 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3860481 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
308784 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
336143 usd
CY2023Q1 us-gaap Revenues
Revenues
39452 usd
CY2022Q1 us-gaap Revenues
Revenues
2744 usd
us-gaap Revenues
Revenues
129620 usd
us-gaap Revenues
Revenues
158424 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
190 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
360 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
35688 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1551367 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
39262 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
2384 usd
us-gaap Gross Profit
GrossProfit
93932 usd
us-gaap Gross Profit
GrossProfit
-1392943 usd
CY2023Q1 us-gaap Selling Expense
SellingExpense
471 usd
CY2022Q1 us-gaap Selling Expense
SellingExpense
60064 usd
us-gaap Selling Expense
SellingExpense
5877 usd
us-gaap Selling Expense
SellingExpense
60064 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
150525 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
589577 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
423117 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1245757 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
150996 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
649641 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
428994 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1305821 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-111734 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-647257 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-335062 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2698764 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
101919 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
55283 usd
us-gaap Interest Expense
InterestExpense
234459 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-213647 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-609530 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-534522 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2741861 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-213647 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-609530 usd
us-gaap Net Income Loss
NetIncomeLoss
-534522 usd
us-gaap Net Income Loss
NetIncomeLoss
-2741861 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-918 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-14888 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-212729 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-609530 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-519634 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2741861 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
59 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
464 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-212670 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-609530 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-519170 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2741861 usd
CY2023Q1 aagh Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
0
CY2022Q1 aagh Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
0
aagh Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
0
aagh Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
0
CY2023Q1 aagh Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
21090938148 shares
CY2022Q1 aagh Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
21089355704 shares
aagh Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
21090454644 shares
aagh Weighted Average Number Of Share Outstanding Basic And Diluted1
WeightedAverageNumberOfShareOutstandingBasicAndDiluted1
21073497199 shares
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-467827 usd
CY2021Q3 aagh Imputed Interest
ImputedInterest
2814 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-331272 usd
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-796285 usd
CY2021Q4 aagh Imputed Interest
ImputedInterest
2723 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-1801058 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2594620 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3860481 usd
CY2022Q3 aagh Imputed Interest
ImputedInterest
5206 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
15200 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
76 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-192754 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4032753 usd
CY2022Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
330 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-128121 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4160544 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
17200 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
59 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-213647 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4356932 usd
us-gaap Net Income Loss
NetIncomeLoss
-534522 usd
us-gaap Net Income Loss
NetIncomeLoss
-2741861 usd
us-gaap Depreciation
Depreciation
6649 usd
us-gaap Depreciation
Depreciation
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
17200 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
aagh Imputed Interest
ImputedInterest
5206 usd
aagh Imputed Interest
ImputedInterest
9921 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
308 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
0 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
9163 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2300 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
140747 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-15197 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1518818 usd
us-gaap Increase Decrease In Customer Advances
IncreaseDecreaseInCustomerAdvances
26019 usd
us-gaap Increase Decrease In Customer Advances
IncreaseDecreaseInCustomerAdvances
44900 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-4363 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
0 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-118396 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
1624 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-800 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-611788 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1318932 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
44420 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16852 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-44420 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16852 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
59340 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
160000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
671528 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
588268 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
15200 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
97500 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
194020 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-291420 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
200184 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
648668 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1045952 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
465 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7075 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-289832 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62643 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
396136 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55568 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106304 usd
us-gaap Interest Paid
InterestPaid
0 usd
us-gaap Interest Paid
InterestPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
800 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
800 usd
us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
0 usd
us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
0 usd
CY2017Q1 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
16155746000 shares
CY2017Q1 us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
100 usd
CY2020Q2 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
510000000 shares
CY2021Q3 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
50000 usd
CY2021Q3 us-gaap Number Of Units In Real Estate Property
NumberOfUnitsInRealEstateProperty
53 pure
CY2021Q3 us-gaap Number Of Real Estate Properties
NumberOfRealEstateProperties
19 pure
CY2021Q3 us-gaap Real Estate Gross At Carrying Value
RealEstateGrossAtCarryingValue
7626286.37 usd
CY2021Q3 us-gaap Payments To Acquire Real Estate
PaymentsToAcquireRealEstate
7000000 usd
CY2021Q3 aagh Real Estate Description Of Terms
RealEstateDescriptionOfTerms
The purchase price shall be paid as follows:(i) $1,000,000 on execution of the Agreement, (ii) $2,000,000 within 60 days thereof and (iii) the remainder by April 10, 2022. The Agreement is subject to customary closing conditions, including, satisfactory due diligence.
CY2021Q4 aagh Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
500000 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2021Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P24M
CY2022Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
500000 shares
CY2021Q4 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
20000000 shares
CY2022Q4 aagh Agreement Description
AgreementDescription
The Company A agrees that if the patent is sold or transferred, Men Hwei, Tsai or Men Hwei, Tsai's successor may receive a 25% gain on the transfer or sale of the interest. The Company agrees to give Men Hwei, Tsai an additional 20 million AAGH shares. The Company allows Men Hwei, Tsai to use three years (from November 26, 2022 to November 25, 2025) find investors each with more than US$10 million investment. In case that no investor is found within three years, Men Hwei, Tsai agrees to return the patent to the Company, and both parties will continue to cooperate in accordance with the original contract on May 18, 2021. If Men Hwei, Tsai finds an investor with an investment of at least US$10 million within three years, and the process for Men Hwei, Tsai and its investors to apply for a new drug may last for several years, then Men Hwei, Tsai agrees that the Company will use the patented technology to develop dietary supplement that are helpful to Alzheimer’s disease. The Company will be responsible for marketing the dietary supplement. Men Hwei, Tsai is entitled to commission equaling to 8% of sales price.
CY2022Q4 us-gaap Other Commitment
OtherCommitment
34978.48 usd
us-gaap Net Income Loss
NetIncomeLoss
-320875 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-215638 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4160544 usd
CY2022Q4 us-gaap Cash
Cash
55568 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Estimates</b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services, debt and equity investment. Actual results could differ from those estimates.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q1 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.01 pure
CY2023Q1 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.01 pure
CY2023Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1053 usd
CY2022Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
3194 usd
CY2023Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
113759 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
116060 usd
CY2023Q1 us-gaap Other Receivables
OtherReceivables
11836 usd
CY2022Q2 us-gaap Other Receivables
OtherReceivables
13836 usd
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
65900 usd
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
62348 usd
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
47859 usd
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
53712 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
113759 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
116060 usd
CY2023Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
243271 usd
CY2022Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
183932 usd
CY2022Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.18 pure
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
100000 usd
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
60000 usd
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
80000 usd
CY2022Q3 us-gaap Interest Paid Net
InterestPaidNet
3616 usd
CY2022Q3 aagh Number Of Loan Agreements
NumberOfLoanAgreements
2 pure
CY2023Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
20000 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
1893421 usd
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
1221892 usd
CY2023Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.20 pure
CY2022Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
100000 usd
CY2022Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.16 pure
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
300000 usd
CY2023Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.12 pure
us-gaap Debt Instrument Term
DebtInstrumentTerm
P1Y
CY2022Q3 us-gaap Debt Instrument Term
DebtInstrumentTerm
P3Y
CY2023Q1 us-gaap Debt Instrument Term
DebtInstrumentTerm
P5Y
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
1533138 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
360283 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
1893421 usd
CY2022Q2 us-gaap Long Term Debt Term
LongTermDebtTerm
P5Y
CY2022Q1 aagh Number Of Unrelated Parties
NumberOfUnrelatedParties
28 pure
CY2022Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.1195
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1310612 usd
CY2022Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
75523 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21093818148 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21090218148 shares
CY2022Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1300000 shares
CY2022Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.075
CY2021Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
48220124 shares
CY2021Q1 aagh Number Of Shareholders
NumberOfShareholders
28 pure
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.00001
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
482 usd
CY2021Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
79362534 shares
CY2021Q1 aagh Number Of Unrelated Parties
NumberOfUnrelatedParties
54 pure
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.00001
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
794 usd
CY2021Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
50000000 shares
CY2021Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.00001
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
500 usd
CY2021Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
6621905 shares
CY2021Q2 aagh Number Of Unrelated Parties
NumberOfUnrelatedParties
12 pure
CY2021Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.00001
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
66 usd
CY2021Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
1300000 shares
CY2021Q2 aagh Number Of Unrelated Parties
NumberOfUnrelatedParties
6 pure
CY2021Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.00001
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
13 usd
CY2021Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
7140000 shares
CY2021Q2 aagh Number Of Unrelated Parties
NumberOfUnrelatedParties
5 pure
CY2021Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.00001
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
71 usd
CY2021Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
450000 shares
CY2021Q2 aagh Number Of Unrelated Parties
NumberOfUnrelatedParties
3 pure
CY2021Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.00001
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
5 usd
CY2021Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
11300000 shares
CY2021Q2 aagh Number Of Unrelated Parties
NumberOfUnrelatedParties
22 pure
CY2021Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.00001
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
113 usd
CY2022Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
10967465 shares
CY2022Q2 aagh Number Of Unrelated Parties
NumberOfUnrelatedParties
1 pure
CY2022Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.0685
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
5173 usd
CY2022Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
240000 shares
CY2022Q2 aagh Number Of Unrelated Parties
NumberOfUnrelatedParties
2 pure
CY2022Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.06495
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
15588 usd
CY2022Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
500000 shares
CY2022Q2 aagh Number Of Unrelated Parties
NumberOfUnrelatedParties
1 pure
CY2022Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.0595
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
29750 usd
CY2022Q2 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
46921 shares
CY2022Q2 aagh Number Of Unrelated Parties
NumberOfUnrelatedParties
1 pure
CY2022Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.0002
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
9 usd
CY2022Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
400000 shares
CY2022Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
100000 usd
CY2022Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.075
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
30000 usd
CY2021Q2 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
20000 usd
CY2021Q2 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
30000 usd
CY2021Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
200000 shares
CY2021Q4 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
240000 shares
CY2021Q4 aagh Stock Shares Not Yet Issued
StockSharesNotYetIssued
60000 shares
CY2021Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
1000000 shares
CY2023Q2 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
1000000 shares
CY2023Q2 aagh Number Of Unrelated Parties
NumberOfUnrelatedParties
2 pure
CY2023Q2 aagh Number Of Loan Agreements
NumberOfLoanAgreements
2 pure
CY2023Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10000 usd
CY2023Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.20 pure
CY2023Q2 us-gaap Debt Instrument Term
DebtInstrumentTerm
P3Y
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
295000 usd
CY2022Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
15000000 shares
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
18104 usd
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
13967 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
60637 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
41901 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
56689 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y6M14D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05 pure
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
40532 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
40532 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
40532 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
710 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
39822 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
39822 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Entity Central Index Key
EntityCentralIndexKey
0001098009

Files In Submission

Name View Source Status
aagh-20230331_cal.xml Edgar Link unprocessable
0001185185-23-000567-index-headers.html Edgar Link pending
0001185185-23-000567-index.html Edgar Link pending
0001185185-23-000567.txt Edgar Link pending
0001185185-23-000567-xbrl.zip Edgar Link pending
aagh-20230331.xsd Edgar Link pending
amgreat20230331_10q.htm Edgar Link pending
ex_524122.htm Edgar Link pending
ex_524123.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
aagh-20230331_def.xml Edgar Link unprocessable
aagh-20230331_pre.xml Edgar Link unprocessable
aagh-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
amgreat20230331_10q_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending